series-b
Stage
4
Investors
About
VBL Therapeutics is a clinical-stage biopharmaceutical company developing targeted antibody therapies for immune-inflammatory diseases using proprietary monocyte targeting technology, with a lead candidate VB-601 entering Phase 1 in early 2023.
Explore VBL Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.